首页> 美国卫生研究院文献>Journal of Carcinogenesis >Restoration of the methylation status of hypermethylated gene promoters by microRNA-29b in human breast cancer: A novel epigenetic therapeutic approach
【2h】

Restoration of the methylation status of hypermethylated gene promoters by microRNA-29b in human breast cancer: A novel epigenetic therapeutic approach

机译:microRNA-29b恢复人乳腺癌中高甲基化基因启动子的甲基化状态:一种新的表观遗传学治疗方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

It is well established that transcriptional silencing of critical tumor-suppressor genes by DNA methylation is a fundamental component in the initiation of breast cancer. However, the involvement of microRNAs (miRNAs) in restoring abnormal DNA methylation patterns in breast cancer is not well understood. Therefore, we investigated whether miRNA-29b, due to its complimentarity to the 3’- untranslated region of DNA methyltransferase 3A (DNMT3A) and DNMT3B, could restore normal DNA methylation patterns in human breast cancers and breast cancer cell lines. We demonstrated that transfection of pre-miRNA-29b into less aggressive MCF-7 cells, but not MDA-MB-231 mesenchymal cells, inhibited cell proliferation, decreased DNMT3A and DNMT3B messenger RNA (mRNA), and decreased promoter methylation status of ADAM23 , CCNA1, CCND2, CDH1, CDKN1C, CDKN2A, HIC1, RASSF1, SLIT2, TNFRSF10D, and TP73 tumor-suppressor genes. Using methylation polymerase chain reaction (PCR) arrays and real-time PCR, we also demonstrated that the methylation status of several critical tumor-suppressor genes increased as stage of breast disease increased, while miRNA-29b mRNA levels were significantly decreased in breast cancers versus normal breast. This increase in methylation status was accompanied by an increase in DNMT1 and DNMT3B mRNA in advanced stage of human breast cancers and in MCF-7, MDA-MB-361, HCC70, Hs-578T, and MDA-MB-231 breast cancer cells as compared to normal breast specimens and MCF-10-2A, a non-tumorigenic breast cell line, respectively. Our findings highlight the potential for a new epigenetic approach in improving breast cancer therapy by targeting DNMT3A and DNMT3B through miRNA-29b in non-invasive epithelial breast cancer cells.
机译:众所周知,DNA甲基化对关键肿瘤抑制基因的转录沉默是引发乳腺癌的基本要素。但是,人们还不太了解microRNA(miRNA)在恢复乳腺癌中异常DNA甲基化模式方面的作用。因此,我们研究了miRNA-29b是否与DNA甲基转移酶3A(DNMT3A)和DNMT3B的3'-非翻译区互补,可以恢复人乳腺癌和乳腺癌细胞系中的正常DNA甲基化模式。我们证明了将pre-miRNA-29b转染至侵袭性较小的MCF-7细胞而非MDA-MB-231间充质细胞中,可抑制细胞增殖,降低DNMT3A和DNMT3B信使RNA(mRNA)并降低ADAM23的启动子甲基化状态, CCNA1,CCND2,CDH1,CDKN1C,CDKN2A,HIC1,RASSF1,SLIT2,TNFRSF10D和TP73肿瘤抑制基因。使用甲基化聚合酶链反应(PCR)阵列和实时PCR,我们还证明,随着乳腺癌疾病分期的增加,一些关键肿瘤抑制基因的甲基化状态也随之增加,而与乳腺癌相比,miRNA-29b mRNA水平显着降低。正常的乳房。这种甲基化状态的增加伴随着人乳腺癌晚期阶段以及MCF-7,MDA-MB-361,HCC70,Hs-578T和MDA-MB-231乳腺癌细胞中DNMT1和DNMT3B mRNA的增加。与正常乳腺标本和非致瘤性乳腺细胞系MCF-10-2A相比。我们的发现突出了通过miRNA-29b将DNMT3A和DNMT3B靶向无创上皮性乳腺癌细胞中的新型表观遗传方法改善乳腺癌治疗的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号